Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	$ 232,000		$ 336,000	$ 550,000
Costs and expenses:
Research and development	3,864,000	$ 5,050,000	7,247,000	8,862,000
General and administrative	2,090,000	2,027,000	3,885,000	3,751,000
Total costs and expenses	5,954,000	7,077,000	11,132,000	12,613,000
Loss from operations	(5,722,000)	(7,077,000)	(10,796,000)	(12,063,000)
Interest expense				(1,000)
Financing costs - warrant liabilities			(28,000)
Change in fair value of warrant liabilities	156,000		1,362,000	0
Change in fair value of derivative asset	(81,000)		(81,000)
Other income (expense), net	16,000	17,000	15,000	42,000
Loss before provision for income taxes	(5,631,000)	(7,060,000)	(9,528,000)	(12,022,000)
Provision for income taxes	0	0	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(5,631,000)	(7,060,000)	(9,528,000)	(12,022,000)
Comprehensive loss	$ (5,631,000)	$ (7,060,000)	$ (9,528,000)	$ (12,022,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic	$ (3.1)	$ (24.54)	$ (6.06)	$ (45.78)
Net loss per share attributable to Vaccinex, Inc. common stockholders, diluted	$ (3.1)	$ (24.54)	$ (6.06)	$ (45.78)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic	1,817,520	287,719	1,572,388	262,623
Weighted-average shares used in computing net loss per share attributable toVaccinex, Inc. common stockholders, diluted	1,817,520	287,719	1,572,388	262,623